SLC5A2 and acute kidney injury: Most studies have reported decreased risks of SGLT2 inhibitors on AKI or impairment in renal function (Nadkarni et al., 2017; Cahn et al., 2019; Heerspink et al., 2020; Koh et al., 2021).